JP7045985B2 - Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法 - Google Patents

Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法 Download PDF

Info

Publication number
JP7045985B2
JP7045985B2 JP2018517399A JP2018517399A JP7045985B2 JP 7045985 B2 JP7045985 B2 JP 7045985B2 JP 2018517399 A JP2018517399 A JP 2018517399A JP 2018517399 A JP2018517399 A JP 2018517399A JP 7045985 B2 JP7045985 B2 JP 7045985B2
Authority
JP
Japan
Prior art keywords
present disclosure
ezh2
medulloblastoma
cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018517399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529742A (ja
JP2018529742A5 (enExample
Inventor
キールハック ハイク
ジェイ． ウォーターズ ナイジェル
ヴィブハカール ラジーバ
Original Assignee
エピザイム，インコーポレイティド
ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・コロラド，ア・ボディー・コーポレイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド, ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・コロラド，ア・ボディー・コーポレイト filed Critical エピザイム，インコーポレイティド
Publication of JP2018529742A publication Critical patent/JP2018529742A/ja
Publication of JP2018529742A5 publication Critical patent/JP2018529742A5/ja
Application granted granted Critical
Publication of JP7045985B2 publication Critical patent/JP7045985B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2018517399A 2015-10-06 2016-10-05 Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法 Expired - Fee Related JP7045985B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562238074P 2015-10-06 2015-10-06
US62/238,074 2015-10-06
US201662299312P 2016-02-24 2016-02-24
US62/299,312 2016-02-24
PCT/US2016/055554 WO2017062495A2 (en) 2015-10-06 2016-10-05 Method of treating medulloblastoma with an ezh2 inhibitor

Publications (3)

Publication Number Publication Date
JP2018529742A JP2018529742A (ja) 2018-10-11
JP2018529742A5 JP2018529742A5 (enExample) 2019-11-07
JP7045985B2 true JP7045985B2 (ja) 2022-04-01

Family

ID=58488487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517399A Expired - Fee Related JP7045985B2 (ja) 2015-10-06 2016-10-05 Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法

Country Status (12)

Country Link
US (2) US20190083504A1 (enExample)
EP (2) EP4309738A3 (enExample)
JP (1) JP7045985B2 (enExample)
KR (1) KR20180058829A (enExample)
CN (1) CN108699046A (enExample)
AU (3) AU2016333982A1 (enExample)
CA (1) CA3000983A1 (enExample)
EA (1) EA201890878A1 (enExample)
IL (2) IL258510A (enExample)
MX (1) MX394355B (enExample)
SG (1) SG10201909413SA (enExample)
WO (1) WO2017062495A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019018635A1 (en) 2017-07-19 2019-01-24 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
EP3976044A4 (en) * 2019-06-03 2024-08-07 Icahn School of Medicine at Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
CN111905102A (zh) * 2020-09-04 2020-11-10 福建医科大学附属第一医院 Ezh2抑制剂在治疗胶质瘤中的应用
KR102821233B1 (ko) 2022-02-10 2025-06-17 서울대학교병원 Hsp70을 표적으로 하는 수모세포종 치료 및 전이 억제 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A3 (en) 2012-10-15 2014-06-19 Epizyme, Inc. Methods of treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4236945A (en) * 1978-11-27 1980-12-02 Allegheny Ludlum Steel Corporation Phosphorus-iron powder and method of producing soft magnetic material therefrom
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
MX373187B (es) * 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
WO2017079757A1 (en) * 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A3 (en) 2012-10-15 2014-06-19 Epizyme, Inc. Methods of treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS Med Chem Lett，2015年03月04日，Vol.6，pp.491-495
Front Oncol，2014年，Vol.4, No.176，pp.1-8

Also Published As

Publication number Publication date
JP2018529742A (ja) 2018-10-11
CA3000983A1 (en) 2017-04-13
EP3371175A2 (en) 2018-09-12
IL258510A (en) 2018-05-31
KR20180058829A (ko) 2018-06-01
IL281318A (en) 2021-04-29
CN108699046A (zh) 2018-10-23
AU2016333982A1 (en) 2018-04-26
EA201890878A1 (ru) 2018-08-31
EP4309738A3 (en) 2024-07-17
SG10201909413SA (en) 2019-11-28
US20190083504A1 (en) 2019-03-21
WO2017062495A2 (en) 2017-04-13
WO2017062495A3 (en) 2017-06-08
AU2021204331A1 (en) 2021-07-22
MX394355B (es) 2025-03-24
MX2018004132A (es) 2018-09-26
AU2023246384A1 (en) 2023-11-02
EP4309738A2 (en) 2024-01-24
EP3371175A4 (en) 2019-09-25
US20200268765A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7013369B2 (ja) Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法
JP2018529742A (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
EP3445749B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
US20230202981A1 (en) Novel small molecules for targeted degradation of untargetable kras in cancer therapy
JP6964450B2 (ja) 造影剤の合成および使用のための組成物、方法およびシステム
JP6890097B2 (ja) リンパ腫を処置するためのｅｚｈ２阻害剤
KR102497728B1 (ko) 림프종 치료를 위한 ｅｚｈ2 억제제
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
JP2018532761A (ja) Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与
JP6509386B2 (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
US20200323865A1 (en) Methods of treating cancer
KR20180042356A (ko) 암 치료 방법
US12521439B2 (en) Methods and materials for modulating Nrf2 pathway
JP2020522687A (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
AU2019299221A1 (en) Activators of the unfolded protein response
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
US10266490B2 (en) Radioprotector compounds
US20240216385A1 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
CN114025766A (zh) 用于抑制gapdh的噁噻嗪化合物
CN105616411A (zh) 治疗结肠癌的组合物及其应用
JP2026514040A (ja) Ｐｓｍａを標的とする放射性医薬品及びｄｎａ損傷応答阻害剤の併用療法
WO2022118966A1 (ja) 細胞内への核酸分子取り込み促進剤、医薬組成物、及び新規化合物
US20250170096A1 (en) Oxphos inhibitors for use in treating cancer
CN104606189B (zh) 一种化合物在制备mTOR抑制剂中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211015

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211026

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211213

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220322

R150 Certificate of patent or registration of utility model

Ref document number: 7045985

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees